title: [Role of AMP-activated protein kinase in renal ischemic preconditioning].
abstract: Kidney transplantation represents the best treatment of end-stage renal disease. In addition to the degree of human leukocyte antigen matching, long-term graft survival is influenced by the quality of the graft before its transplantation. Quality criteria include the level of ischemic damage caused by the transplantation per se. Renal ischemic preconditioning (IP) consists of different approaches to prevent ischemia/reperfusion (I/R) damage induced by the interruption and recovery of renal circulation, as observed during transplantation. Distinct animal models show promising results regarding the efficiency of PCI to preserve kidney structure and function in I/R conditions. Characterizing the cellular cascades involved in I/R led to the identification of putative targets of renal IP, including the adenosine monophosphate-activated protein kinase (AMPK). AMPK is a ubiquitous energy sensor, which has been implicated in the maintenance of epithelial cell polarization under energy deprivation. Among others, the anti-diabetic drug, metformin, is a potent activator of AMPK. Here, we summarize the in vitro and in vivo data about the role of AMPK in renal IP. Defining the pharmacological conditions of IP would help to improve the quality of the renal graft before its transplantation, thereby increasing its long-term survival.
authors.affiliation: Service de néphrologie, université de Liège CHU (ULg CHU), CHU de Liège, tour 1, 6(e) étage, avenue de l'Hôpital, 1 B-4000 Liège, Belgique.
authors.forename: Pauline
authors.initials: P
authors.lastname: Erpicum
authors.affiliation: Service de néphrologie, université de Liège CHU (ULg CHU), CHU de Liège, tour 1, 6(e) étage, avenue de l'Hôpital, 1 B-4000 Liège, Belgique; GIGA Cardiovascular Sciences, université de Liège, tour 3, 5(e) étage, avenue de l'Hôpital, 1 B-4000 Liège, Belgique.
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Krzesinski
authors.affiliation: Service de néphrologie, université de Liège CHU (ULg CHU), CHU de Liège, tour 1, 6(e) étage, avenue de l'Hôpital, 1 B-4000 Liège, Belgique; GIGA Cardiovascular Sciences, université de Liège, tour 3, 5(e) étage, avenue de l'Hôpital, 1 B-4000 Liège, Belgique. Electronic address: francois.jouret@chu.ulg.ac.be.
authors.forename: François
authors.initials: F
authors.lastname: Jouret
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000187:drug effects / Q000502:physiology*; D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D004734:Energy Metabolism / Q000502:physiology; D004789:Enzyme Activation / Q000187:drug effects; D004847:Epithelial Cells / Q000201:enzymology / Q000648:ultrastructure; D006085:Graft Survival; D006801:Humans; D007511:Ischemia / Q000209:etiology / Q000503:physiopathology; D019194:Ischemic Preconditioning; D007668:Kidney / Q000098:blood supply*; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation / Q000379:methods; D008687:Metformin / Q000494:pharmacology / Q000627:therapeutic use; D018384:Oxidative Stress; D051381:Rats; D017207:Rats, Sprague-Dawley; D012079:Renal Circulation; D015427:Reperfusion Injury / Q000517:prevention & control*; D012265:Ribonucleotides / Q000494:pharmacology / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D012265:Ribonucleotides; D000620:Aminoimidazole Carboxamide; D008687:Metformin; D055372:AMP-Activated Protein Kinases; C031143:AICA ribonucleotide
keywords: AMP-activated protein kinase; Ischemic preconditioning; Kidney transplantation; Metformin; Metformine; Préconditionnement ischémique; Transplantation rénale